(Q36895805)

16 August 2017

1 reference

title

TRAIL-receptor antibodies as a potential cancer treatment (English)

1 reference

16 August 2017

Donald J Buchsbaum

1

1 reference

16 August 2017

Andres Forero-Torres

series ordinal

2

1 reference

16 August 2017

Albert F LoBuglio

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

405-409

1 reference

16 August 2017

4

1 reference

TRAIL receptor-targeted therapy.

16 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Targeting TRAIL agonistic receptors for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

TRAIL signalling: decisions between life and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Eradication of established tumors in mice by a combination antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.405

21 January 2018

Identifiers

DOI

10.2217/14796694.3.4.405

1 reference

16 August 2017

1 reference